Interferon- (IFN-) dose, schedule, and response
| Variable . | Values . | No. of Patients with Available Data . |
|---|---|---|
| Median duration of IFN-α therapy, mo (range) | 2 (1-39) | 144 |
| Median starting dose, ×106 U/d (range) | 3 (1-10) | 130 |
| Median maximum dose, ×106 U/d (range) | 6 (1-25) | 129 |
| Schedule, n (%) | 148 | |
| Continuous therapy | 130 (88) | |
| Intermittent therapy | 18 (12) | |
| Hydroxyurea given concomitantly | 91 (59) | 154 |
| Best response to IFN-α, n (%) | 156 | |
| None | 24 (15) | |
| Hematologic, no cytogenetic | 52 (33) | |
| Hematologic, unknown cytogenetic | 45 (29) | |
| Minimal cytogenetic | 15 (10) | |
| Minor cytogenetic | 5 (3) | |
| Major cytogenetic | 9 (6) | |
| Complete cytogenetic | 6 (4) | |
| Reason for stopping IFN-α, n (%) | 161 | |
| Transplantation | 121 (75) | |
| Did not tolerate | 15 (9) | |
| No or inadequate response | 18 (11) | |
| Disease progression after response | 3 (2) | |
| Other | 4 (3) |
| Variable . | Values . | No. of Patients with Available Data . |
|---|---|---|
| Median duration of IFN-α therapy, mo (range) | 2 (1-39) | 144 |
| Median starting dose, ×106 U/d (range) | 3 (1-10) | 130 |
| Median maximum dose, ×106 U/d (range) | 6 (1-25) | 129 |
| Schedule, n (%) | 148 | |
| Continuous therapy | 130 (88) | |
| Intermittent therapy | 18 (12) | |
| Hydroxyurea given concomitantly | 91 (59) | 154 |
| Best response to IFN-α, n (%) | 156 | |
| None | 24 (15) | |
| Hematologic, no cytogenetic | 52 (33) | |
| Hematologic, unknown cytogenetic | 45 (29) | |
| Minimal cytogenetic | 15 (10) | |
| Minor cytogenetic | 5 (3) | |
| Major cytogenetic | 9 (6) | |
| Complete cytogenetic | 6 (4) | |
| Reason for stopping IFN-α, n (%) | 161 | |
| Transplantation | 121 (75) | |
| Did not tolerate | 15 (9) | |
| No or inadequate response | 18 (11) | |
| Disease progression after response | 3 (2) | |
| Other | 4 (3) |